PT  - JOURNAL ARTICLE
AU  - Lova Sun
AU  - Sanjna Surya
AU  - Anh N. Le
AU  - Heena Desai
AU  - Abigail Doucette
AU  - Peter Gabriel
AU  - Marylyn Ritchie
AU  - Daniel Rader
AU  - Ivan Maillard
AU  - Erin Bange
AU  - Alexander Huang
AU  - Robert H. Vonderheide
AU  - Angela DeMichele
AU  - Anurag Verma
AU  - Ronac Mamtani
AU  - Kara N. Maxwell
TI  - Rates of COVID-19-related Outcomes in Cancer compared to non-Cancer Patients
AID  - 10.1101/2020.08.14.20174961
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.14.20174961
4099  - http://medrxiv.org/content/early/2020/08/16/2020.08.14.20174961.short
4100  - http://medrxiv.org/content/early/2020/08/16/2020.08.14.20174961.full
AB  - Cancer patients are a vulnerable population postulated to be at higher risk for severe COVID-19 infection. Increased COVID-19 morbidity and mortality in cancer patients may be attributable to age, comorbidities, smoking, healthcare exposure, and cancer treatments, and partially to the cancer itself. Most studies to date have focused on hospitalized patients with severe COVID-19, thereby limiting the generalizability and interpretability of the association between cancer and COVID-19 severity. We compared outcomes of SARS-CoV-2 infection in 323 patients enrolled prior to the pandemic in a large academic biobank (n=67 cancer patients and n=256 non-cancer patients). After adjusting for demographics, smoking status, and comorbidities, a diagnosis of cancer was independently associated with higher odds of hospitalization (OR 2.16, 95% CI 1.12-4.18) and 30-day mortality (OR 5.67, CI 1.49-21.59). These associations were primarily driven by patients with active cancer. These results emphasize the critical importance of preventing SARS-CoV-2 exposure and mitigating infection in cancer patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institutes of Health (P30-CA016520 to Abramson Cancer Center)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PMBB is approved under IRB protocol# 813913 and supported by Perelman School of Medicine at University of Pennsylvania.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request and subject to data use agreement. The data are not publicly available due to information that could compromise the privacy of research participants.